Cargando…
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the inco...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773640/ https://www.ncbi.nlm.nih.gov/pubmed/28303438 http://dx.doi.org/10.1007/s10198-017-0871-0 |
_version_ | 1783293604343578624 |
---|---|
author | Angelis, Aris Lange, Ansgar Kanavos, Panos |
author_facet | Angelis, Aris Lange, Ansgar Kanavos, Panos |
author_sort | Angelis, Aris |
collection | PubMed |
description | BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment. METHODS: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) ‘Responsibilities and structure of HTA agencies’; (2) ‘Evidence and evaluation criteria considered in HTAs’; (3) ‘Methods and techniques applied in HTAs’; and (4) ‘Outcomes and implementation of HTAs’. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts. RESULTS: All countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional ‘social value judgements’ (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making. CONCLUSION: More comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-017-0871-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5773640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-57736402018-01-30 Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries Angelis, Aris Lange, Ansgar Kanavos, Panos Eur J Health Econ Original Paper BACKGROUND: Although health technology assessment (HTA) systems base their decision making process either on economic evaluations or comparative clinical benefit assessment, a central aim of recent approaches to value measurement, including value based assessment and pricing, points towards the incorporation of supplementary evidence and criteria that capture additional dimensions of value. OBJECTIVE: To study the practices, processes and policies of value-assessment for new medicines across eight European countries and the role of HTA beyond economic evaluation and clinical benefit assessment. METHODS: A systematic (peer review and grey) literature review was conducted using an analytical framework examining: (1) ‘Responsibilities and structure of HTA agencies’; (2) ‘Evidence and evaluation criteria considered in HTAs’; (3) ‘Methods and techniques applied in HTAs’; and (4) ‘Outcomes and implementation of HTAs’. Study countries were France, Germany, England, Sweden, Italy, Netherlands, Poland and Spain. Evidence from the literature was validated and updated through two rounds of feedback involving primary data collection from national experts. RESULTS: All countries assess similar types of evidence; however, the specific criteria/endpoints used, their level of provision and requirement, and the way they are incorporated (e.g. explicitly vs. implicitly) varies across countries, with their relative importance remaining generally unknown. Incorporation of additional ‘social value judgements’ (beyond clinical benefit assessment) and economic evaluation could help explain heterogeneity in coverage recommendations and decision-making. CONCLUSION: More comprehensive and systematic assessment procedures characterised by increased transparency, in terms of selection of evaluation criteria, their importance and intensity of use, could lead to more rational evidence-based decision-making, possibly improving efficiency in resource allocation, while also raising public confidence and fairness. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10198-017-0871-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2017-03-16 2018 /pmc/articles/PMC5773640/ /pubmed/28303438 http://dx.doi.org/10.1007/s10198-017-0871-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Angelis, Aris Lange, Ansgar Kanavos, Panos Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries |
title | Using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight European countries |
title_full | Using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight European countries |
title_fullStr | Using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight European countries |
title_full_unstemmed | Using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight European countries |
title_short | Using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight European countries |
title_sort | using health technology assessment to
assess the value of new medicines: results of a systematic review and expert
consultation across eight european countries |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773640/ https://www.ncbi.nlm.nih.gov/pubmed/28303438 http://dx.doi.org/10.1007/s10198-017-0871-0 |
work_keys_str_mv | AT angelisaris usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries AT langeansgar usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries AT kanavospanos usinghealthtechnologyassessmenttoassessthevalueofnewmedicinesresultsofasystematicreviewandexpertconsultationacrosseighteuropeancountries |